NASDAQ:INAB

IN8bio Stock Forecast, Price & News

$5.50

-0.36 (-6.14%)

(As of 12/1/2021 12:00 AM ET)

Add

Compare

Today's Range: $5.40
▼
$5.94
50-Day Range: $5.50
▼
$8.97
52-Week Range: $5.40
▼
$10.32

Volume: 11,579 shs
Average Volume: 32,992 shs
Market Capitalization: $103.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive INAB News and Ratings via Email

Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter.

About IN8bio

IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company's principal candidate includes INB-200, which are in clinical stage. IN8bio Inc. is based in New York.

IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer
November 16, 2021 | finance.yahoo.com

FY2021 EPS Estimates for IN8bio Inc (NASDAQ:INAB) Lifted by B. Riley
November 15, 2021 | americanbankingnews.com

IN8bio (NASDAQ:INAB) Announces Earnings Results
November 11, 2021 | americanbankingnews.com

IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors
November 11, 2021 | finance.yahoo.com

IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 10, 2021 | finance.yahoo.com

IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO
November 4, 2021 | finance.yahoo.com

Here's Why We're Not Too Worried About IN8bio's (NASDAQ:INAB) Cash Burn Situation
November 1, 2021 | nasdaq.com

Possible turnaround for IN8bio, Inc. (NASDAQ:INAB) insiders, still down US$241k after a US$1.0m shopping spree
November 1, 2021 | finance.yahoo.com

IN8bio’s Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme
October 27, 2021 | finance.yahoo.com

IN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021
October 4, 2021 | finance.yahoo.com

IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
September 10, 2021 | finance.yahoo.com

IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference
August 30, 2021 | finance.yahoo.com

Mizuho Initiates Coverage On IN8bio with Buy Rating, Announces Price Target of $12
August 26, 2021 | benzinga.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INAB
Previous Symbol
CUSIP: N/A
CIK: 1740279
Web: www.in8bio.com
Phone: 646-600-6438
Fax: N/A
Employees: 7
Year Founded: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 18,755,000
Free Float: N/A
Market Cap: $103.15 million
Optionable: Not Optionable

Company Calendar

Last Earnings: 11/10/2021
Today: 12/02/2021
Fiscal Year End: 12/31/2021
Next Earnings (Estimated): 2/09/2022

MarketRank^™

Overall MarketRank^™

1.78 out of 5 stars

Medical Sector

838th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

129th out of 202 stocks

3.5 Analyst's Opinion

Consensus Rating
IN8bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.50, IN8bio has a forecasted upside of 181.8% from its current price of $5.50.
Amount of Analyst Coverage
IN8bio has only been the subject of 1 research reports in the past 90 days.

4.8 Community Rank

Outperform Votes
IN8bio has received 5 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
IN8bio has received 2 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
IN8bio has received 71.43% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about IN8bio and other stocks. Vote “Outperform” if you believe INAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INAB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
IN8bio does not currently pay a dividend.
Dividend Growth
IN8bio does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IN8bio insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 35.40% of the stock of IN8bio is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for IN8bio are expected to grow in the coming year, from ($1.42) to ($0.97) per share.

See Top Rated MarketRank™ Stocks Here

IN8bio (NASDAQ:INAB) Frequently Asked Questions

Is IN8bio a buy right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IN8bio stock.
View analyst ratings for IN8bio or view top-rated stocks.
When is IN8bio's next earnings date?: IN8bio is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for IN8bio.
How were IN8bio's earnings last quarter?: IN8bio Inc (NASDAQ:INAB) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.11.
View IN8bio's earnings history.
What price target have analysts set for INAB?: 2 Wall Street analysts have issued 1-year target prices for IN8bio's shares. Their forecasts range from $12.00 to $19.00. On average, they anticipate IN8bio's stock price to reach $15.50 in the next year. This suggests a possible upside of 181.8% from the stock's current price.
View analysts' price targets for IN8bio or view top-rated stocks among Wall Street analysts.
Who are some of IN8bio's key competitors?: Some companies that are related to IN8bio include CEL-SCI (CVM), Innate Pharma (IPHA), Cellectis (CLLS), Passage Bio (PASG), Innate Pharma (IPHYF), Jounce Therapeutics (JNCE), MiNK Therapeutics (INKT), Ambrx Biopharma (AMAM), Lineage Cell Therapeutics (LCTX), SQZ Biotechnologies (SQZ), DBV Technologies (DBVT), Cabaletta Bio (CABA), Jasper Therapeutics (JSPR), Acumen Pharmaceuticals (ABOS) and Compugen (CGEN).
View all of INAB's competitors.
When did IN8bio IPO?: (INAB) raised $44 million in an initial public offering on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities acted as the underwriter for the IPO.
What is IN8bio's stock symbol?: IN8bio trades on the NASDAQ under the ticker symbol "INAB."
When does the company's lock-up period expire?: IN8bio's lock-up period expires on Wednesday, January 26th. IN8bio had issued 4,000,000 shares in its public offering on July 30th. The total size of the offering was $40,000,000 based on an initial share price of $10.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
Who are IN8bio's major shareholders?: IN8bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Capital World Investors (4.27%), B. Riley Financial Inc. (1.37%), Voss Capital LLC (0.43%), Tudor Investment Corp Et Al (0.34%) and Millennium Management LLC (0.14%).
Which institutional investors are buying IN8bio stock?: INAB stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, B. Riley Financial Inc., Voss Capital LLC, Tudor Investment Corp Et Al, and Millennium Management LLC.
How do I buy shares of IN8bio?: Shares of INAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IN8bio's stock price today?: One share of INAB stock can currently be purchased for approximately $5.50.
How much money does IN8bio make?: IN8bio has a market capitalization of $103.15 million.
How many employees does IN8bio have?: IN8bio employs 7 workers across the globe.
What is IN8bio's official website?: The official website for IN8bio is www.in8bio.com.
Where are IN8bio's headquarters?: IN8bio is headquartered at 79 Madison Avenue, New York, New York 10016.
How can I contact IN8bio?: IN8bio's mailing address is 79 Madison Avenue, New York, New York 10016. The company can be reached via phone at 646-600-6438.

This page was last updated on 12/2/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

IN8bio Stock Forecast, Price & News

About IN8bio

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Company Calendar

MarketRank™

Overall MarketRank™

3.5 Analyst's Opinion

4.8 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

0.0 Company Ownership

0.6 Earnings and Valuation

IN8bio (NASDAQ:INAB) Frequently Asked Questions

Is IN8bio a buy right now?

When is IN8bio's next earnings date?

How were IN8bio's earnings last quarter?

What price target have analysts set for INAB?

Who are some of IN8bio's key competitors?

When did IN8bio IPO?

What is IN8bio's stock symbol?

When does the company's lock-up period expire?

Who are IN8bio's major shareholders?

Which institutional investors are buying IN8bio stock?

How do I buy shares of IN8bio?

What is IN8bio's stock price today?

How much money does IN8bio make?

How many employees does IN8bio have?

What is IN8bio's official website?

Where are IN8bio's headquarters?

How can I contact IN8bio?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™